Jubilant Pharmova reports strong half-year growth and strategic expansions

Jubilant Pharmova reported a 12% year-over-year increase in Q2 FY26 consolidated revenue to INR 1,966 Cr., with H1 FY26 revenue growing 11% to INR 3,867 Cr. The company's normalized PAT for Q2 FY26 saw a 21% rise to INR 124 Cr., and H1 FY26 normalized PAT grew 32% to INR 227 Cr. This growth was attributed to strong performance in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and CRDMO businesses, coupled with reduced finance costs.

Key operational highlights include the launch of the third sterile fill and finish line at the Spokane Manufacturing Facility, with technology transfer programs initiating revenue generation. Commercial batch production is expected to commence in FY27. The company is investing $50 million to expand its PET radiopharmacy network from 3 to 9 sites, targeting full operation by FY28. Additionally, Jubilant Pharmova plans to launch 6-8 new products annually in its Generics segment across US and non-US international markets, alongside new PET and SPECT imaging products with a total addressable market of $550 Mn.

The board also approved the grant of 1,506 Stock Options/Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. These options will vest at the end of the 3rd year and be exercisable within a maximum of one year from the vesting date. The exercise price for these shares is Re. 1 per equity share.